Dr Reddy's Laboratories reported a 36 per cent increase in its consolidated profit after tax at Rs 1,307 crore for the ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.26% to 1,235.20 Indian rupees Monday, on what proved to be an all-around dismal trading session for the stock market, with the BSE SENSEX ...

Apotex has gotten a tentative nod from the US Food and Drug Administration (USFDA) for semaglutide. Meanwhile, Dr Reddy's is ...

Stay updated with the Dr Reddys Stock Liveblog, your one-stop destination for real-time information and analysis of a leading ...

Oil & gas, consumable fuels, and healthcare sector emerged as top gainers including stocks such as Tata Motors (TATAMOTORS), ...

Dr. Reddy's Laboratories Ltd. closed 11.64% short of its 52-week high of 1,377.95 rupees, which the company reached on June 12th.

Add Yahoo as a preferred source to see more of our stories on Google. SHREVEPORT, La. (KTAL/KMSS) – Dr. Reddy’s Laboratories, a global pharmaceutical company, recently closed in early 2025 due to ...

The brokerage flagged concerns after Dr Reddy’s semaglutide product, Embeltah, was denied registration by Brazil’s health ...

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

ETHealthworld.com brings latest dr reddy news, views and updates from all top sources for the Indian Health industry.